Advertisement
Canada markets closed

  • S&P/TSX

    21,969.24
    +83.86 (+0.38%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CAD/USD

    0.7316
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    86,239.27
    -1,753.23 (-1.99%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • RUSSELL 2000

    2,002.00
    +20.88 (+1.05%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,927.90
    +316.14 (+2.03%)
     

  • VOLATILITY

    15.03
    -0.34 (-2.21%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6838
    +0.0017 (+0.25%)
     

Today's Research Reports on ABcann Global, Medicure, Aphria and Acerus Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI Initiates Coverage on:

ABcann Global Corporation
https://rdinvesting.com/news/?ticker=ABCN.V

Medicure Inc.
https://rdinvesting.com/news/?ticker=MPH.V

Aphria Inc.
https://rdinvesting.com/news/?ticker=APH.TO

Acerus Pharmaceuticals Corporation
https://rdinvesting.com/news/?ticker=ASP.TO

ADVERTISEMENT

ABcann Global's stock jumped 6.78% Tuesday, to close the day at $1.26. The stock recorded a trading volume of 2,566,808 shares, which was above its three months average volume of 621,001 shares. In the last year, ABcann Global's shares have traded in a range of 0.80 - 4.06. The share price has gained 57.50% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.31 is below its 200-day moving average of $1.81. Shares of ABcann Global have fallen approximately 17.65 percent year-to-date.

Access RDI's ABcann Global Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ABCN.V

On Tuesday, shares of Medicure recorded a trading volume of 4,410 shares, which was below the three months average volume of 14,700 shares. The stock ended the day 0.72% lower at 6.88. The share price has gained 23.74% from its 52 week low with a 52 week trading range of 5.56 - 9.20. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $7.10 is greater than its 200-day moving average of $6.95. Shares of the company are trading at a Price to Earnings ratio of 2.50. Shares of Medicure have fallen approximately 7.65 percent year-to-date.

Access RDI's Medicure Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MPH.V

Aphria's stock moved 3.51% higher Tuesday, to close the day at $11.51. The stock recorded a trading volume of 2,974,876 shares, which was below its three months average volume of 3,923,948 shares. In the last year, Aphria's shares have traded in a range of 5.62 - 24.75. The share price has gained 104.80% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $11.61 is below its 200-day moving average of $13.08. Shares of the company are trading at a Price to Earnings ratio of 55.87. Shares of Aphria have fallen approximately 38.45 percent year-to-date.

Access RDI's Aphria Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APH.TO

On Tuesday, shares of Acerus Pharmaceuticals recorded a trading volume of 80,900 shares, which was below the three months average volume of 224,818 shares. The stock ended the day flat at 0.235. The share price has gained 135.00% from its 52 week low with a 52 week trading range of 0.10 - 0.52. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.26 is below its 200-day moving average of $0.29. Shares of Acerus Pharmaceuticals have fallen approximately 17.24 percent year-to-date.

Access RDI's Acerus Pharmaceuticals Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ASP.TO

Our Actionable Research on ABcann Global Corporation (TSXV:ABCN.V) and Medicure Inc. (TSXV:MPH.V) and Aphria Inc. (TSX:APH.TO) and Acerus Pharmaceuticals Corporation (TSX:ASP.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com